Galapagos, Idenix Ink Hepatitis and HIV Drug-Discovery Pact
Galapagos NV and Idenix Pharmaceuticals will collaborate on hepatitis and HIV infectious disease programs, Galapagos said last week.
Under the agreement, which is worth up to $2.5 million over two years, BioFocus, Galapagos' service division, will supply Idenix with its SoftFocus chemical compound collections. BioFocus will provide hit-to-lead and lead-optimization services.
Galapagos will receive technology access fees for SoftFocus, fee components for medicinal chemistry services, and success payments after identifying pre-clinical candidates. The amounts were not specified.
Lentigen Closes Seed, Series A Financing Round
Lentigen said this week that it has secured its seed and series A financing from Greenwich Biotech Ventures.
Terms of the financing were not disclosed.
The company said the funding will allow it to launch its current programs in lentiviral vector development, add commercial scale manufacturing capabilities, and increase its infrastructure.
Antisense Pharma Raises $18M in Financing Round
German antisense drug developer Antisense Pharma said this week that it has raised $18 million in venture financing.
The funds were received from German-based MIG funds.
"The investment by the MIG funds provides substantial funding of our advanced clinical program designed to obtain approval of our antisense drug, AP 12009, which we are developing for patients with malignant tumors including brain tumors and pancreatic cancer", Reimar Schlingensiepen, founder and COO of Antisense Pharma, said in a statement.
IDT Expands Oligo Manufacturing Center Hours of Operation
Integrated DNA Technologies said this week that it has expanded the operating schedule of its main oligonucleotide production center to 7:30 am to 10:00 pm eastern time.
The move, the company said, will allow its customers to order their products later each day.